SHENZHEN, China, July 31,
2024 /PRNewswire/ -- On July
28 2024, Kexing Biopharm announced European Commission
approval of Apexelsin®, the generic drug to Bristol
Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel).
Apexelsin® is developed by WhiteOak Pharmaceutical B.V.
and Kexing Biopharm is in charge of the commercialization of this
product out of US.
Nanoparticle albumin-bound paclitaxel offers significant
advantages for clinical use, providing improved safety and higher
patient compliance, compared to solvent-based paclitaxel and
liposomal paclitaxel. It is widely accepted in the clinical setting
and holds crucial value in oncology. Furthermore, the European
Society for Medical Oncology (ESMO) guidelines recommend it as a
first-line treatment for metastatic pancreatic cancer and non-small
cell lung cancer (NSCLC), as well as a second-line option for
breast cancer. Breast cancer is one of the
common cancer types in women in the EU region, and there is a large
market space for breast cancer treatment drugs.
In recent years, the Chinese pharmaceutical industry has
embarked on a significant expansion into international markets. But
actually, Kexing Biopharm began its international ventures 20 years
ago with its core products. In recent years, the company has
introduced more than a dozen high-quality Chinese medications to
emerging markets, improving accessibility to medicines for local
patients.
The approval of albumin-bound paclitaxel by the EU will enhance
the company's competitiveness in the international pharmaceutical
market. It also signifies that Kexing Biopharm, in addition to its
long-established presence in emerging markets, is expanding its
commercialization efforts into the European market. The EU market
represents an important milestone in the company's overseas
commercialization strategy. To date, Kexing Biopharm is proceeding
with the registration of Apexelsin® in dozens of emerging market out of
Europe. With the successful launch of this product
in the EU, Kexing Biopharm will further expand its global sales
reach, serving more patients and healthcare providers.
View original
content:https://www.prnewswire.com/news-releases/kexing-biopharms-albumin-bound-paclitaxel-granted-eu-market-approval-302210949.html
SOURCE Kexing Biopharm